Press Release: So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results

Dow Jones03-25 17:15

BEIJING, March 25, 2026 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025.

Fourth Quarter 2025 Financial Highlights

   -- Total revenues were RMB460.7 million (US$65.9 million[1]), compared with 
      RMB369.2 million in the corresponding period of 2024. The aesthetic 
      treatment services revenues were RMB248.1 million (US$35.5 million), 
      compared with RMB81.3 million in the corresponding period of 2024, 
      exceeding the high end of guidance. 
 
   -- Net loss attributable to So-Young International Inc. was RMB108.8 million 
      (US$15.6 million), compared with net loss attributable to So-Young 
      International Inc. of RMB607.6 million in the same period of 2024. 
 
   -- Non-GAAP net loss attributable to So-Young International Inc.[2] was 
      RMB93.4 million (US$13.2 million), compared with non-GAAP net loss 
      attributable to So-Young International Inc. of RMB53.2 million in the 
      same period of 2024. 

Fourth Quarter 2025 Operational Highlights

   -- The number of verified treatment visits to the branded aesthetic centers 
      for the quarter reached over 125,000, compared with approximately 45,000 
      in the same period of 2024. The number of verified aesthetic treatments 
      performed surpassed 289,400, compared with approximately 107,900 in the 
      same period of 2024. 
 
   -- The number of active users, defined as those who visited branded 
      aesthetic centers at least once during the 12-month period ended on 
      December 31, 2025, exceeded 171,000, compared with approximately 52,700 
      users during the corresponding period in 2024. 
 
   -- The number of core members grew by over 14,500 during the quarter, 
      representing an approximately 39% sequential increase. Both the revenue 
      contribution from core members to aesthetic treatment services and their 
      quarterly repurchase rate exceeded 80%. 
 
   -- As of December 31, 2025, So-Young had 49 fully operational branded 
      aesthetic centers (48 directly-operated, 1 franchised) across fifteen 
      major cities: Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chengdu, 
      Wuhan, Chongqing, Ningbo, Changsha, Tianjin, Xi'an, Suzhou, Hefei and 
      Kunming. Among them, 25 centers achieved profitability* in the fourth 
      quarter. In addition, 39 centers generated positive quarterly operating 
      cash flow* in the fourth quarter. The following table shows the revenues 
      generated by So-Young aesthetic centers, categorized by their phase of 
      development: 
 
([1]) This press release contains translations of certain Renminbi (RMB) 
amounts into U.S. dollars (US$) solely for the convenience of the reader. 
Unless otherwise specified, all translations of Renminbi amounts into U.S. 
dollar amounts in this press release are made at RMB6.9931 to US$1.00, which 
was the U.S. dollars middle rate announced by the Board of Governors of the 
Federal Reserve System of the United States on December 31, 2025. 
([2]) Non-GAAP net income/(loss) attributable to So-Young International Inc. 
is defined as net income/(loss) attributable to So-Young International Inc. 
excluding share-based compensation expenses, impairment of goodwill and 
long-lived assets attributable to So-Young International Inc., impairment of 
long-term investment attributable to So-Young International Inc., allowance 
for credit loss from loans to investees attributable to So-Young International 
Inc., gain/(loss) on disposal of long-term investment and fair value change of 
long-term investment attributable to So-Young International Inc., and tax 
effects on non-GAAP adjustments. See "Reconciliation of GAAP and Non-GAAP 
Results" at the end of this press release. 
 
 
Phase**                                    Average Revenue 
(Operating         Number of  Revenue      per Center        Average Center 
duration)           Centers    (RMB)       (RMB)             Age (Month) 
-----------------  ---------  -----------  ----------------  ----------------- 
Ramp-up (0-3 
 months)                  13   16,598,000         1,277,000                1.2 
-----------------  ---------  -----------  ----------------  ----------------- 
Growth (4-12 
 months)                  19   88,955,000         4,682,000                7.1 
-----------------  ---------  -----------  ----------------  ----------------- 
Maturity (over 12 
 months)                  17  142,523,000         8,384,000               17.8 
-----------------  ---------  -----------  ----------------  ----------------- 
 
 
* Center-level profitability measures whether an individual aesthetic center 
achieved positive profit in a given period. It is calculated by deducting 
consumable materials costs, personnel costs, center rental expenses, center 
depreciation expenses, and other center-level operating costs from the 
company's self-operated store revenues, before allocation of any back-office 
or mid-office expenses. Quarterly operating cash flow refers to total cash 
collected from orders less center-level operating payments in a given period, 
and excluding operating expense payments made by back-office or mid-office 
departments during the same period. Center-level profitability and quarterly 
operating cash flow are metrics derived from the Company's internal management 
accounts, which have not been audited. 
** For the purposes of this table, "Phase" refers to the length of time since 
commencement of actual operations rather than the legal establishment or 
registration date of a branded aesthetic center. In cases where a center has 
been relocated, merged, or its team and customer base transferred to another 
location, the operating duration of the branded aesthetic center is calculated 
from the commencement date of the predecessor center's operations. Periods 
during which a center is temporarily closed and not conducting external 
operations (e.g., due to renovation or other suspensions of business) are 
excluded from the calculation of operating duration. Branded aesthetic centers 
that have been converted to other uses or are no longer within the reporting 
scope are excluded from the statistics. 
 

Fiscal Year 2025 Financial Highlights

   -- Total revenues were RMB1,523.4 million (US$217.8 million) in fiscal year 
      2025, compared with RMB1,466.7 million in the prior year. 
 
   -- Net loss attributable to So-Young International Inc. was RMB242.3 million 
      (US$34.6 million) in fiscal year 2025, compared with a net loss 
      attributable to So-Young International Inc. of RMB589.5 million in the 
      prior year. 
 
   -- Non-GAAP net loss attributable to So-Young International Inc. was 
      RMB217.1 million (US$31.0 million) in fiscal year 2025, compared with a 
      non-GAAP net loss attributable to So-Young International Inc. of RMB4.7 
      million in the prior year. 

Extension of Share Repurchase Program

The share repurchase program, initially approved on March 18, 2024, authorizing the repurchase of up to US$25 million in ADSs or ordinary shares, has been extended for an additional 12-month period through March 31, 2027. In 2024 and 2025, the Company repurchased approximately 4.8 million ADSs. All other terms remain unchanged.

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, "In the fourth quarter, our aesthetic center business maintained its strong momentum, solidifying its role as a core growth engine for the Group. We have retained our position as China's leading light medical aesthetics chain by scale, which serves as a clear validation of our business model's strength and sustainability. Looking ahead, we will pursue steady store expansion while prioritizing operational excellence and industry-leading standards. Through strategic alliances with upstream manufacturers and a commitment to genuine product traceability, we are building competitive advantages rooted in both unit economics and trust. We are confident that this disciplined approach will drive sustainable value for our shareholders."

Fourth Quarter 2025 Financial Results

Revenues

Total revenues were RMB460.7 million (US$65.9 million), an increase of 24.8% from RMB369.2 million in the same period of 2024. The increase was primarily due to business expansion of the branded aesthetic centers.

   -- Aesthetic treatment services revenues were RMB248.1 million (US$35.5 
      million), an increase of 205.3% from RMB81.3 million in the same period 
      of 2024. The increase was primarily due to the business expansion of the 
      branded aesthetic centers. 
 
   -- Information and reservation services[3] revenues were RMB125.7 million 
      (US$18.0 million), a decrease of 26.8% from RMB171.6 million in the same 
      period of 2024. The decrease was primarily due to a decrease in the 
      number of medical service providers subscribing to information services 
      on So-Young's platform. 
 
   -- Sales of medical products and maintenance services revenues were RMB69.3 
      million (US$9.9 million), a decrease of 19.9% from RMB86.4 million in the 
      same period of 2024, primarily due to a decrease in the order volume for 
      medical equipment. 
 
   -- Other services revenues were RMB17.7 million (US$2.5 million), a decrease 
      of 40.7% from RMB29.9 million in the same period of 2024, primarily due 
      to a decrease in revenues from So-Young Prime. 
 
([3]) Since the second quarter of 2025, in light of the better monitoring 
business development of branded aesthetic centers, the previous line item 
information, reservation services and others was separated into two line 
items, which are information and reservation services and other services. 
The revenue generated from information and reservation services and other 
services for the fourth quarter of 2024 have also been retrospectively 
updated. The amount reclassified from previous line item information, 
reservation services and others to information and reservation services is 
RMB171.6 million for the fourth quarter of 2024. 
 

Cost of Revenues

Cost of revenues was RMB255.9 million (US$36.6 million), an increase of 67.2% from RMB153.1 million in the fourth quarter of 2024. The increase was primarily due to business expansion of the branded aesthetic centers.

   -- Cost of aesthetic treatment services was RMB189.0 million (US$27.0 
      million), an increase of 189.9% from RMB65.2 million in the fourth 
      quarter of 2024. The increase was primarily due to the business expansion 
      of the branded aesthetic centers. 
 
   -- Cost of information and reservation services[4] was RMB10.1 million 
      (US$1.4 million), a decrease of 50.6% from RMB20.4 million in the fourth 
      quarter of 2024. The decrease was in line with the decrease in revenue 
      generated from information and reservation services. 
 
   -- Cost of medical products sold and maintenance services was RMB41.6 
      million (US$5.9 million), a decrease of 4.0% from RMB43.3 million in the 
      fourth quarter of 2024. The decrease was primarily due to a decrease in 
      costs associated with the sales of medical equipment. 
 
   -- Cost of other services was RMB15.3 million (US$2.2 million), a decrease 
      of 36.7% from RMB24.1 million in the fourth quarter of 2024. The decrease 
      was primarily due to a decrease in costs associated with So-Young Prime. 
 
([4]) Since the second quarter of 2025, the previous line item cost of 
information, reservation services and others was separated into two line 
items, which are cost of information and reservation services and cost of 
other services. Cost of information and reservation services primarily 
consists of expenditures relating to operation of platform business, and the 
remaining cost of information, reservation services and others is reclassified 
into cost of other services. The cost of information and reservation services 
and cost of other services for the fourth quarter of 2024 have also been 
retrospectively reclassified. 
 

Operating Expenses

Total operating expenses were RMB327.7 million (US$46.9 million), a decrease of 59.8% from RMB815.2 million in the fourth quarter of 2024.

   -- Sales and marketing expenses were RMB168.7 million (US$24.1 million), an 
      increase of 25.8% from RMB134.0 million in the fourth quarter of 2024. 
      The increase was primarily attributable to an increase in expenses 
      associated with branding and user acquisition activities for the branded 
      aesthetic centers. 
 
   -- General and administrative expenses were RMB101.9 million (US$14.6 
      million), an increase of 3.5% from RMB98.4 million in the fourth quarter 
      of 2024. The increase was primarily due to the business expansion of the 
      branded aesthetic centers. 
 
   -- Research and development expenses were RMB37.4 million (US$5.4 million), 
      a decrease of 12.4% from RMB42.8 million in the fourth quarter of 2024. 
      The decrease was primarily attributable to improvements in staff 
      efficiency. 
 
   -- Impairment of goodwill and long-lived assets was RMB19.7 million (US$2.8 
      million) in this quarter, representing the amount by which the carrying 
      amount of certain asset exceeds their fair value, based on an annual 
      long-lived assets impairment assessment. Impairment of goodwill was 
      RMB540.0 million in the fourth quarter of 2024. 

Income Tax Benefits/(Expenses)

Income tax benefits were RMB0.6 million (US$0.1 million), compared with income tax expenses of RMB2.1 million in the same period of 2024.

Net Loss Attributable to So-Young International Inc.

Net loss attributable to So-Young International Inc. was RMB108.8 million (US$15.6 million), compared with a net loss attributable to So-Young International Inc. of RMB607.6 million in the fourth quarter of 2024.

Non-GAAP Net Loss Attributable to So-Young International Inc.

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, impairment of goodwill and long-lived assets attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments, was RMB93.4 million (US$13.2 million), compared with RMB53.2 million non-GAAP net loss attributable to So-Young International Inc. in the same period of 2024.

Basic and Diluted Loss per ADS

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB1.08 (US$0.15) and RMB1.08 (US$0.15), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB5.92 and RMB5.92, respectively, in the same period of 2024.

Fiscal Year 2025 Financial Results

Revenues

Total revenues were RMB1,523.4 million (US$217.8 million), an increase of 3.9% from RMB1,466.7 million in fiscal year 2024.

   -- Aesthetic treatment services revenues were RMB674.9 million (US$96.5 
      million), an increase of 298.7% from RMB169.3 million in fiscal year 
      2024. The increase was primarily due to the business expansion of the 
      branded aesthetic centers. 
 
   -- Information and reservation services revenues were RMB499.7 million 
      (US$71.5 million), a decrease of 32.2% from RMB736.6 million in fiscal 
      year 2024. The decrease was primarily due to a decrease in the number of 
      medical service providers subscribing to information services on 
      So-Young's platform. 
 
   -- Sales of medical products and maintenance services revenues were RMB267.8 
      million (US$38.3 million), a decrease of 27.2% from RMB368.0 million in 
      fiscal year 2024, primarily due to a decrease in sales of medical 
      equipment. 
 
   -- Other services revenues were RMB81.0 million (US$11.6 million), a 
      decrease of 58.0% from RMB192.8 million in the same period of 2024, 
      primarily due to a decrease in revenues from So-Young Prime. 

Cost of Revenues

Cost of revenues was RMB795.7 million (US$113.8 million), an increase of 40.2% from RMB567.6 million in fiscal year 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

   -- Cost of aesthetic treatment services was RMB518.7 million (US$74.2 
      million), an increase of 294.2% from RMB131.6 million in fiscal year 
      2024. The increase was primarily due to the business expansion of the 
      branded aesthetic centers. 
 
   -- Cost of information and reservation services was RMB63.0 million (US$9.0 
      million), a decrease of 41.1% from RMB107.0 million in fiscal year 2024. 
      The decrease was in line with the decrease in revenue generated from 
      information and reservation services. 
 
   -- Cost of medical products sold and maintenance services was RMB147.1 
      million (US$21.0 million), a decrease of 19.7% from RMB183.2 million in 
      fiscal year 2024. The decrease was primarily due to a decrease in costs 
      associated with the sales of medical equipment. 
 
   -- Cost of other services was RMB66.9 million (US$9.6 million), a decrease 
      of 54.1% from RMB145.9 million in fiscal year of 2024. The decrease was 
      primarily due to a decrease in costs associated with So-Young Prime. 

Operating Expenses

Total operating expenses were RMB1,013.9 million (US$145.0 million), a decrease of 33.5% from RMB1,523.6 million in fiscal year 2024.

   -- Sales and marketing expenses were RMB528.6 million (US$75.6 million), an 
      increase of 6.9% from RMB494.5 million in fiscal year 2024. The increase 
      was primarily attributable to an increase in expenses associated with 
      branding and user acquisition activities for the branded aesthetic 
      centers. 
 
   -- General and administrative expenses were RMB328.5 million (US$47.0 
      million), an increase of 1.4% from RMB324.1 million in fiscal year 2024. 
      The increase was primarily due to the business expansion of the branded 
      aesthetic centers. 
 
   -- Research and development expenses were RMB137.0 million (US$19.6 million), 
      a decrease of 17.0% from RMB165.0 million in fiscal year 2024. The 
      decrease was primarily attributable to improvements in staff efficiency. 
 
   -- Impairment of goodwill and long-lived assets was RMB19.7 million (US$2.8 
      million) in this year, representing the amount by which the carrying 
      amount of certain asset exceeds their fair value, based on an annual 
      long-lived assets impairment assessment. Impairment of goodwill was 
      RMB540.0 million in fiscal year 2024. 

Income Tax (Expenses)/Benefits

Income tax expenses were RMB0.8 million (US$0.1 million), compared with an income tax benefits of RMB0.9 million in fiscal year 2024.

Net Loss Attributable to So-Young International Inc.

Net loss attributable to So-Young International Inc. was RMB242.3 million (US$34.6 million), compared with a net loss attributable to So-Young International Inc. of RMB589.5 million in fiscal year 2024.

Non-GAAP Net Loss Attributable to So-Young International Inc.

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, impairment of goodwill and long-lived assets attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments, was RMB217.1 million (US$31.0 million), compared with a non-GAAP net loss attributable to So-Young International Inc. of RMB4.7 million in fiscal year 2024.

Basic and Diluted Loss per ADS

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB2.39 (US$0.34) and RMB2.39 (US$0.34), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB5.72 and RMB5.72 in fiscal year 2024.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of December 31, 2025, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB936.4 million (US$133.9 million), compared with RMB1,253.2 million as of December 31, 2024, primarily due to an increase of investment in branded aesthetic centers.

Business Outlook

For the first quarter of 2026, So-Young expects aesthetic treatment services revenues to be between RMB268.0 million (US$38.3 million) and RMB278.0 million (US$39.8 million), representing a 171.2% to 181.3% increase from the same period in 2025. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income/(loss) attributable to So-Young International Inc. by excluding share-based compensation expenses and impairment of goodwill and long-lived assets from income/(loss) from operations, and excluding share-based compensation expenses, impairment of goodwill and long-lived assets, impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments from net income/(loss) attributable to So-Young International Inc., respectively. Starting from the fourth quarter of 2024, the Company newly included impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments as additional adjustments in its non-GAAP financial measures, which may result in differences from previously disclosed non-GAAP figures.

The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses (i) that are not expected to result in cash payments or (ii) that are non-recurring in nature or may not be indicative of the Company's core operating results and business outlook. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses, the impairment of goodwill and long-lived assets, impairment of long-term investment and allowance for credit loss from loans to investees are non-cash in nature. Gain/(loss) on disposal of long-term investment and fair value change of long-term investment are non-recurring in nature. And, in substance, both impairment of long-term investment and allowance for credit loss from loans to investees are impairment of investment. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses, impairment of goodwill and long-lived assets, impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

Conference Call Information

So-Young's management will hold an earnings conference call on Wednesday, March 25, 2026, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

 
International:    +1-412-902-4272 
Mainland China:   4001-201203 
US:               +1-888-346-8982 
Hong Kong:        +852-800-905-945 
Passcode:         So Young 
 

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, April 1, 2026. The dial-in details are:

 
International:   +1-412-317-0088 
US:              +1-855-669-9658 
Passcode:        5232304 
 

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company") is the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments. The Company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, delivering high-quality treatments, and developing, producing and distributing optoelectronic medical equipment and injectable products. With its strong brand recognition, digital reach, affordable treatments and efficient supply chain, So-Young is well-positioned to serve its audience over the long term and grow along the medical aesthetic value chain.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations

Ms. Mona Qiao

Phone: +86-10-8790-2012

E-mail: ir@soyoung.com

Christensen

Ms. Charlie Chi

Phone: +86-10-5900-1548

E-mail: sy@christensencomms.com

 
                       SO-YOUNG INTERNATIONAL INC. 
             UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS 
       (Amounts in thousands, except for share and per share data) 
 
                                                   As of 
                                  ---------------------------------------- 
                                  December 31,  December 31,  December 31, 
                                      2024          2025          2025 
                                  ------------  ------------  ------------ 
                                      RMB           RMB           US$ 
Assets 
Current assets: 
Cash and cash equivalents              587,749       418,213        59,804 
Restricted cash and term 
 deposits                               66,367        64,683         9,250 
Trade receivables                       98,774        51,532         7,369 
Inventories                            151,754       233,389        33,374 
Receivables from online payment 
 platforms                              24,255        16,296         2,330 
Amounts due from related parties         1,218           774           111 
Term deposits and short-term 
 investments                           599,041       453,472        64,846 
Prepayment and other current 
 assets                                195,202       246,237        35,211 
                                  ------------  ------------  ------------ 
Total current assets                 1,724,360     1,484,596       212,295 
                                  ------------  ------------  ------------ 
Non-current assets: 
Long-term investments                  280,281       274,753        39,289 
Intangible assets                      126,615       144,097        20,606 
Goodwill                                   684           684            98 
Property and equipment, net            155,352       293,560        41,979 
Deferred tax assets                     84,950        69,313         9,912 
Operating lease right-of-use 
 assets                                162,764       251,635        35,983 
Other non-current assets               200,152       130,998        18,732 
                                  ------------  ------------  ------------ 
Total non-current assets             1,010,798     1,165,040       166,599 
                                  ------------  ------------  ------------ 
Total assets                         2,735,158     2,649,636       378,894 
                                  ============  ============  ============ 
 
Liabilities 
Current liabilities: 
Short-term borrowings                   69,771        39,814         5,693 
Taxes payable                           61,862        43,461         6,215 
Contract liabilities                    76,579        65,948         9,430 
Salary and welfare payables            111,396       130,170        18,614 
Amounts due to related parties             477           618            88 
Accrued expenses and other 
 current liabilities                   265,216       427,507        61,134 
Operating lease 
 liabilities-current                    44,905        76,536        10,945 
                                  ------------  ------------  ------------ 
Total current liabilities              630,206       784,054       112,119 
                                  ------------  ------------  ------------ 
Non-current liabilities: 
Operating lease liabilities-non 
 current                               125,200       183,364        26,221 
Deferred tax liabilities                19,758        10,615         1,518 
Other non-current liabilities            1,264         2,783           398 
                                  ------------  ------------  ------------ 
Total non-current liabilities          146,222       196,762        28,137 
                                  ------------  ------------  ------------ 
Total liabilities                      776,428       980,816       140,256 
                                  ============  ============  ============ 
Shareholders' equity: 
Treasury stock                       (376,690)     (391,944)      (56,047) 
Class A ordinary shares 
 (US$0.0005 par value; 
 750,000,000   shares authorized 
 as of December 31, 2024 and 
 December   31, 2025; 77,897,969 
 and 65,659,510 shares issued 
 and   outstanding as of 
 December 31, 2024, 79,016,808 
 and   65,089,482 shares issued 
 and outstanding as of December 
   31, 2025, respectively)                 253           257            37 
Class B ordinary shares 
 (US$ 0.0005 par value; 
 20,000,000   shares authorized 
 as of December 31, 2024 and 
 December   31, 2025; 12,000,000 
 shares issued and outstanding 
 as of   December 31, 2024 and 
 December 31, 2025)                         37            37             5 
Additional paid-in capital           3,069,799     3,059,764       437,540 
Statutory reserves                      40,552        46,448         6,642 
Accumulated deficit                  (926,390)   (1,174,587)     (167,964) 
Accumulated other comprehensive 
 income                                 31,560        13,340         1,908 
                                  ------------  ------------  ------------ 
 
Total So-Young International 
 Inc. shareholders' equity           1,839,121     1,553,315       222,121 
                                  ------------  ------------  ------------ 
Non-controlling interests              119,609       115,505        16,517 
Total shareholders' equity           1,958,730     1,668,820       238,638 
                                  ------------  ------------  ------------ 
 
Total liabilities and 
 shareholders' equity                2,735,158     2,649,636       378,894 
                                  ============  ============  ============ 
 
 
                               SO-YOUNG INTERNATIONAL INC. 
                UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
               (Amounts in thousands, except for share and per share data) 
 
                        For the Three Months Ended         For the Fiscal Year Ended 
                      ------------------------------  ----------------------------------- 
                                            December 
                      December   December     31,      December     December    December 
                       31, 2024   31, 2025    2025      31, 2024     31, 2025    31, 2025 
                      ---------  ---------  --------  -----------  -----------  --------- 
                         RMB        RMB       US$         RMB          RMB         US$ 
 
Revenues: 
Aesthetic treatment 
 services                81,267    248,076    35,474      169,263      674,903     96,510 
Information and 
 reservation 
 services               171,624    125,675    17,971      736,607      499,685     71,454 
Sales of medical 
 products and 
 maintenance 
 services                86,432     69,257     9,904      367,980      267,839     38,300 
Other services           29,888     17,714     2,533      192,848       80,983     11,580 
                      ---------  ---------  --------  -----------  -----------  --------- 
 
Total revenues          369,211    460,722    65,882    1,466,698    1,523,410    217,844 
Cost of revenues: 
Cost of aesthetic 
 treatment services    (65,208)  (189,017)  (27,029)    (131,580)    (518,749)   (74,180) 
Cost of information 
 and reservation 
 services              (20,384)   (10,071)   (1,440)    (106,958)     (62,970)    (9,005) 
Cost of medical 
 products sold and 
 maintenance 
 services              (43,325)   (41,595)   (5,948)    (183,164)    (147,110)   (21,036) 
Cost of other 
 services              (24,134)   (15,265)   (2,183)    (145,883)     (66,894)    (9,566) 
                      ---------  ---------  --------  -----------  -----------  --------- 
Total cost of 
 revenues             (153,051)  (255,948)  (36,600)    (567,585)    (795,723)  (113,787) 
                      ---------  ---------  --------  -----------  -----------  --------- 
Gross profit            216,160    204,774    29,282      899,113      727,687    104,057 
Operating expenses: 
Sales and marketing 
 expenses             (134,045)  (168,678)  (24,121)    (494,493)    (528,591)   (75,588) 
General and 
 administrative 
 expenses              (98,420)  (101,893)  (14,571)    (324,073)    (328,523)   (46,978) 
Research and 
 development 
 expenses              (42,753)   (37,436)   (5,353)    (165,030)    (137,040)   (19,596) 
Impairment of 
 goodwill and 
 long-lived assets    (540,009)   (19,710)   (2,818)    (540,009)     (19,710)    (2,818) 
Total operating 
 expenses             (815,227)  (327,717)  (46,863)  (1,523,605)  (1,013,864)  (144,980) 
                      ---------  ---------  --------  -----------  -----------  --------- 
Loss from operations  (599,067)  (122,943)  (17,581)    (624,492)    (286,177)   (40,923) 
Other 
income/(expenses): 
Investment income, 
 net                      7,623        773       111       11,020        1,738        249 
Interest income, net      8,237      3,453       494       46,507       23,556      3,368 
Exchange 
 (losses)/gains           (763)      2,929       419          112        5,948        851 
Impairment of 
 long-term 
 investment             (7,350)         --        --      (7,350)           --         -- 
Share of losses of 
 equity method 
 investee               (3,413)      (616)      (88)     (15,015)      (4,076)      (583) 
Others, net            (11,103)      1,670       238        1,131       12,902      1,845 
                      ---------  ---------  --------  -----------  -----------  --------- 
Loss before tax       (605,836)  (114,734)  (16,407)    (588,087)    (246,109)   (35,193) 
Income tax 
 (expenses)/benefits    (2,126)        619        89          905        (796)      (114) 
                      ---------  ---------  --------  -----------  -----------  --------- 
Net loss              (607,962)  (114,115)  (16,318)    (587,182)    (246,905)   (35,307) 
Net loss/(income) 
 attributable to 
 noncontrolling 
 interests                  386      5,266       753      (2,345)        4,604        658 
                      ---------  ---------  --------  -----------  -----------  --------- 
Net loss 
 attributable to 
 So-Young 
 International Inc.   (607,576)  (108,849)  (15,565)    (589,527)    (242,301)   (34,649) 
                      =========  =========  ========  ===========  ===========  ========= 
 
 
                              SO-YOUNG INTERNATIONAL INC. 
         UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued) 
              (Amounts in thousands, except for share and per share data) 
 
                     For the Three Months Ended      For the Fiscal Year Ended 
                 ----------------------------------  ---------------------------------- 
                  December    December    December    December    December    December 
                  31, 2024    31, 2025    31, 2025    31, 2024    31, 2025    31, 2025 
                 ----------  ----------  ----------  ----------  ----------  ---------- 
                    RMB         RMB         US$         RMB         RMB         US$ 
 
Net loss per 
ordinary share 
Net loss per 
 ordinary share 
 attributable 
 to ordinary 
 shareholder - 
 basic               (7.70)      (1.40)      (0.20)      (7.43)      (3.11)      (0.44) 
Net loss per 
 ordinary share 
 attributable 
 to ordinary 
 shareholder - 
 diluted             (7.70)      (1.40)      (0.20)      (7.43)      (3.11)      (0.44) 
Net loss per 
 ADS 
 attributable 
 to ordinary 
 shareholders - 
 basic (13 ADS 
   represents 
 10 Class A 
 ordinary 
 shares)             (5.92)      (1.08)      (0.15)      (5.72)      (2.39)      (0.34) 
Net loss per 
 ADS 
 attributable 
 to ordinary 
 shareholders - 
 diluted (13 
 ADS 
   represents 
 10 Class A 
 ordinary 
 shares)             (5.92)      (1.08)      (0.15)      (5.72)      (2.39)      (0.34) 
Weighted 
 average number 
 of ordinary 
 shares used in 
 computing loss 
 per share, 
   basic*        78,905,617  77,593,230  77,593,230  79,384,454  77,863,698  77,863,698 
Weighted 
 average number 
 of ordinary 
 shares used in 
 computing loss 
 per share, 
   diluted*      78,905,617  77,593,230  77,593,230  79,384,454  77,863,698  77,863,698 
 
Share-based 
compensation 
expenses 
included in: 
Cost of 
 revenues              (34)           4           1       (289)       (185)        (26) 
Sales and 
 marketing 
 expenses             (239)          30           4       (659)       (835)       (119) 
General and 
 administrative 
 expenses           (1,731)         771         110    (29,527)     (7,118)     (1,018) 
Research and 
 development 
 expenses             (211)          66           9     (2,180)       (780)       (112) 
 
* Both Class A and Class B ordinary shares are included in the calculation of the 
weighted average number of ordinary shares outstanding, basic and diluted. 
 
 
                           SO-YOUNG INTERNATIONAL INC. 
                   Reconciliation of GAAP and Non-GAAP Results 
           (Amounts in thousands, except for share and per share data) 
 
                    For the Three Months Ended       For the Fiscal Year Ended 
                  ------------------------------  -------------------------------- 
                                        December                        December 
                  December   December     31,     December   December     31, 
                   31, 2024   31, 2025    2025     31, 2024   31, 2025    2025 
                  ---------  ---------  --------  ---------  ---------  -------- 
                     RMB        RMB       US$        RMB        RMB       US$ 
 
GAAP loss from 
 operations       (599,067)  (122,943)  (17,581)  (624,492)  (286,177)  (40,923) 
Add back: 
 Share-based 
 compensation 
 expenses             2,215      (871)     (124)     32,655      8,918     1,275 
Add back: 
 Impairment of 
 goodwill and 
 long-lived 
 assets             540,009     19,710     2,818    540,009     19,710     2,818 
Non-GAAP loss 
 from 
 operations        (56,843)  (104,104)  (14,887)   (51,828)  (257,549)  (36,830) 
                  =========  =========  ========  =========  =========  ======== 
 
 
GAAP net loss 
 attributable to 
 So-Young 
 International 
 Inc.             (607,576)  (108,849)  (15,565)  (589,527)  (242,301)  (34,649) 
Add back: 
 Share-based 
 compensation 
 expenses             2,215      (871)     (124)     32,655      8,918     1,275 
Add back: 
 Impairment of 
 goodwill and 
 long-lived 
 assets 
 attributable to 
 So-   Young 
 International 
 Inc.               540,009     18,782     2,818    540,009     18,782     2,686 
Add back: 
 Impairment of 
 long-term 
 investment 
 attributable to 
 So-Young 
   International 
 Inc.                 7,350         --        --      7,350         --        -- 
Add back: 
 Allowance for 
 credit loss 
 from loans to 
 investees 
 attributable to 
 So-   Young 
 International 
 Inc.                13,843         --        --     13,843         --        -- 
Reversal: Gain 
 on disposal of 
 long-term 
 investment and 
 fair value 
 change of 
   long-term 
 investment 
 attributable to 
 So-Young 
 International 
 Inc.               (7,791)         --        --    (7,791)         --        -- 
Reversal: Tax 
 effects on 
 non-GAAP 
 adjustments 
 (1)                (1,276)    (2,483)     (355)    (1,276)    (2,483)     (355) 
Non-GAAP net 
 loss 
 attributable to 
 So-Young 
 International 
 Inc.              (53,226)   (93,421)  (13,226)    (4,737)  (217,084)  (31,043) 
                  =========  =========  ========  =========  =========  ======== 
 
(1) To adjust the income tax effects of non-GAAP adjustments, which is primarily 
related to allowance for credit loss from loans to investees, gain/(loss) on 
disposal of long-term investment, fair value change of long-term investment and 
impairment of long-lived assets. Other non-GAAP adjustment items have no tax 
effect, because full valuation allowances were provided for related deferred tax 
assets as it is more-likely-than-not they will not be realized. 
 

View original content:https://www.prnewswire.com/news-releases/so-young-reports-unaudited-fourth-quarter-and-fiscal-year-2025-financial-results-302724647.html

SOURCE So-Young International Inc.

 

(END) Dow Jones Newswires

March 25, 2026 05:15 ET (09:15 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment